drugset
drugset / Trial / NCT05556226

Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants

NCT05556226 ↗

Phase 1 Completed 40 enrolled AbbVie
RandomizedParallel-groupOpen-labelBasic science

Summary

This study will assess how safe ABBV-154 is and how ABBV-154 moves through the body of adult healthy participants. Adverse Events will be assessed. ABBV-154 is an investigational drug being developed for potential treatment of immune-mediated inflammatory diseases. Participants are randomly assigned to one of the 2 treatment groups. Approximately 40 adult healthy volunteers will be enrolled in 2 sites in the United States. All participants will receive ABBV-154 as subcutaneous injections with one of the 2 different formulations. There may be higher burden for participants in this trial. Participants will be confined for 9 days. Adverse Events and blood tests will be performed.

Timeline

Start
2022-10-18
Primary completion
2023-02-17
Completion
2023-02-17

Drugs

EvaluationDrugModalityDoseRoute
Subject ADALIMUMAB FOSIMDESONIDE Unknown — Subcutaneous

Indications

No indication recorded.